Хірургічне втручання у пацієнтів, які проходять антитромбоцитарну терапію 7 страница

483. Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, Ziada KM,­Brennan DM, Ellis SG, Topol EJ. Lack of benefit from intravenous platelet glycoprotein­IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions­of aortocoronary bypass grafts: a pooled analysis of five randomized clinical­trials. Circulation 2002;106(24):3063–3067

484. Baim DS,Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ,­Ho KK, Kuntz RE, Saphenous vein graft Angioplasty Free of Emboli Randomized­Trial I. Randomized trial of a distal embolic protection device during percutaneous­intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;­105(11):1285–190

485. StoneGW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P,­Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ,­Ramee S, Cox DA, FilterWire EXREI. Randomized comparison of distal protection­with a filter-based catheter and a balloon occlusion and aspiration system during­percutaneous intervention of diseased saphenous vein aorto-coronary bypass­grafts. Circulation 2003;108(5):548–553

486. Mauri L, Cox D,Hermiller J, Massaro J,Wahr J, TaySW, Jonas M, Popma JJ, Pavliska J,­Wahr D, Rogers C. The PROXIMAL trial: proximal protection during saphenous­vein graft intervention using the Proxis Embolic Protection System: a randomized,­prospective, multicenter clinical trial. J Am Coll Cardiol 2007;50(15):1442–1449

487. Naidu SS, Turco MA, Mauri L, Coolong A, Popma JJ, Kereiakes DJ. Contemporary­incidence and predictors of major adverse cardiac events after saphenous vein graft­intervention with embolic protection (an AMEthyst trial substudy). Am J Cardiol­2010;105(8):1060–1064

488. Giugliano GR, Falcone MW, Mego D, Ebersole D, Jenkins S, Das T, Barker E,­Ruggio JM, Maini B, Bailey SR. A prospective multicenter registry of laser therapy­for degenerated saphenous vein graft stenosis: the COronary graft Results following­Atherectomy with Laser (CORAL) trial. Cardiovasc Revasc Med 2012;13(2):­84–89

489. Frobert O, Schersten F, James SK, Carlsson J, Lagerqvist B. Long-term safety and­efficacy of drug-eluting and bare metal stents in saphenous vein grafts. Am Heart J­2012;164(1):87–93

490. Wiisanen ME, Abdel-Latif A, Mukherjee D, Ziada KM. Drug-eluting stents vs. baremetal­stents in saphenous vein graft interventions: a systematic review and­meta-analysis. JACC Cardiovasc Interv 2010;3(12):1262–1273

491. Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T,­Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV,­Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. Continued benefit­from paclitaxel-eluting compared with bare-metal stent implantation in saphenous­vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous­Vein Grafts) trial. JACC Cardiovasc Interv 2011;4(2):176–182

492. Hakeem A, Helmy T, Munsif S, Bhatti S, Mazraeshahi R, Cilingiroglu M, Effat M,­Leesar M, Arif I. Safety and efficacy of drug eluting stents compared with bare­metal stents for saphenous vein graft interventions: a comprehensive meta-analysis­of randomized trials and observational studies comprising 7,994 patients. Catheter­Cardiovasc Interv 2011;77(3):343–355

493. Mamas MA, Foley J, Nair S, Wiper A, Clarke B, El-Omar M, Fraser DG, Khattar R,­Neyses L, Fath-Ordoubadi F. A comparison of drug-eluting stents vs. bare metal­stents in saphenous vein graft PCI outcomes: a meta-analysis. J Interv Cardiol­2011;24(2):172–180

494. Ko DT, Guo H, Wijeysundera HC, Zia MI, Dzavik V, Chu MW, Fremes SE,­Cohen EA, Tu JV. Long-term safety and effectiveness of drug-eluting stents for­the treatment of saphenous vein grafts disease: a population-based study. JACC Cardiovasc­Interv 2011;4(9):965–973

495. Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J,­Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ,­Richardt G, Schomig A, Kastrati A. Drug-eluting vs. bare-metal stents in saphenous­vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet­2011;378(9796):1071–1078

496. Nauta ST, Van Mieghem NM, Magro M, Deckers JW, Simsek C, Van Geuns RJ, Van­Der Giessen WJ, De Jaegere P, Regar E, Van Domburg RT, SerruysPW. Seven-year­safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein­bypass grafts. Catheter Cardiovasc Interv 2012;79(6):912–918

497. Alam M, Bandeali SJ, Virani SS, Jneid HM, Shahzad SA, Ramanathan KB, Kar B,­Kleiman NS, Lakkis N. Clinical outcomes of percutaneous interventions in saphenous­vein grafts using drug-eluting stents compared to bare-metal stents: a comprehensive­meta-analysisof all randomized clinical trials. Clin Cardiol 2012;35(5):­291–296

498. Brilakis ES, Lasala JM, Cox DA, Berger PB, Bowman TS, Starzyk RM, Dawkins KD Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous­vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: AMulticenter­Safety Surveillance) program. JACC Cardiovasc Interv 2010;3(7):742–750

499. Seshadri N, Whitlow PL, Acharya N, Houghtaling P, Blackstone EH, Ellis SG. Emergency­coronary artery bypass surgery in the contemporary percutaneous coronary­intervention era. Circulation 2002;106(18):2346–2350

500. Richardson SG, Morton P, Murtagh JG, O’Keeffe DB, Murphy P, Scott ME. Management­of acute coronary occlusion during percutaneous transluminal coronary­angioplasty: experience of complications in a hospital without on site facilities for­cardiac surgery. BMJ 1990;300(6721):355–358

501. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H,­Schmitt C, Dirschinger J, Schomig A. Sirolimus-eluting stent or paclitaxel-eluting­stent vs.balloon angioplasty for prevention of recurrences in patients with coronary­in-stent restenosis: a randomized controlled trial. JAMA 2005;293(2):165–171

502. Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL,­Schomig A, Kastrati A. Randomized trial of paclitaxel- vs. sirolimus-eluting stents­for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE­2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for­In-Stent Restenosis 2) study. J Am Coll Cardiol 2010;55(24):2710–2716

503. Alfonso F, Perez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V,­Lopez-Minguez JR, Angel J, Mantilla R, Moris C, Cequier A, Sabate M, Escaned J,­Moreno R, Banuelos C, Suarez A, Macaya C. A randomized comparison of­sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis:­results of the Restenosis Intrastent: Balloon Angioplasty Vs. Elective­Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol 2006;47(11):2152–2160

504. Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, Lopez-Minguez JR,­Angel J, Auge JM, Gomez-Recio M, Moris C, Seabra-Gomes R,­Perez-Vizcayno MJ, Macaya C. A randomized comparison of repeat stenting with­balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol 2003;­42(5):796–805

505. Dibra A, Kastrati A, Alfonso F, Seyfarth M, Perez-Vizcayno MJ, Mehilli J, Schomig A Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis:­meta-analysis of randomized trials. J Am Coll Cardiol 2007;49(5):616–623

506. Scheller B, Clever YP, Kelsch B, Hehrlein C, Bocksch W, Rutsch W, Haghi D,­Dietz U, Speck U, Bohm M, Cremers B. Long-term follow-up after treatment of­coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc­Interv 2012;5(3):323–330

507. Scheller B, Hehrlein C, BockschW, RutschW, Haghi D, Dietz U, Bohm M, Speck U Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter N Engl J Med 2006;355(20):2113–2124

508. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C,­Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M,­Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B. Paclitaxel-coated­balloon catheter vs. paclitaxel-coated stent for the treatment of coronary in-stent­restenosis. Circulation 2009;119(23):2986–2994

509. Rittger H, Brachmann J, Sinha AM,Waliszewski M, Ohlow M, Brugger A, Thiele H,­Birkemeyer R, Kurowski V, Breithardt OA, Schmidt M, Zimmermann S, Lonke S,­von Cranach M, Nguyen TV, Daniel WG, Wohrle J. A randomized, multicenter,­single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain­balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study J Am Coll Cardiol 2012;59(15):1377–1382

510. Habara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H, Katoh H, Oka N,­Fuku Y, Hosogi S, Hirono A, Maruo T, Tanaka H, Shigemoto Y, Hasegawa D,­Tasaka H, Kusunose M, Otsuru S, Okamoto Y, Saito N, Tsujimoto Y, Eguchi H,­Miyake K, Yoshino M. Effectiveness of paclitaxel-eluting balloon catheter in patients­with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv 2011;4(2):149–154

511. Byrne RA, Neumann FJ, Mehilli J, Pinieck S,Wolff B, Tiroch K, Schulz S, Fusaro M,­Ott I, Ibrahim T, Hausleiter J, Valina C, Pache J, Laugwitz KL, Massberg S,­Kastrati A. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty­in patients with restenosis after implantation of a drug-eluting stent (ISARDESIRE­3): a randomised, open-label trial. Lancet 2013;381(9865):461–467

512. Indermuehle A, Bahl R, Lansky AJ, Froehlich GM, Knapp G, Timmis A, Meier P Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and­meta-analysis of randomised controlled trials. Heart 2013;99(5):327–333

513. Tousek P, Pavei A, Oreglia J, Martin G, Sharif F, Fajadet J, Farah B. Impact of atherosclerotic­disease progression on mid-term clinical outcome in diabetic patients in­the drug-eluting stent era. EuroIntervention 2009;4(5):588–592

514. Zellweger MJ, Kaiser C, Jeger R, Brunner-La Rocca HP, Buser P, Bader F,­Mueller-Brand J, Pfisterer M. Coronary artery disease progression late after successful­stent implantation. J Am Coll Cardiol 2012;59(9):793–799

515. Chechi T, Vecchio S, Vittori G, Giuliani G, Lilli A, Spaziani G, Consoli L,­Baldereschi G, Biondi-Zoccai GG, Sheiban I, Margheri M. ST-segment elevation­myocardial infarction due to early and late stent thrombosis a new group of highrisk­patients. J Am Coll Cardiol 2008;51(25):2396–2402

516. Alfonso F, Dutary J, Paulo M, Gonzalo N, Perez-Vizcayno MJ, Jimenez-Quevedo P,­Escaned J, Banuelos C, Hernandez R, Macaya C. Combineduse of optical coherence­tomography and intravascular ultrasound imaging in patients undergoing coronary­interventions for stent thrombosis. Heart 2012;98(16):1213–1220

517. Armstrong EJ, FeldmanDN,WangTY, Kaltenbach LA, Yeo KK,Wong SC, Spertus J,­Shaw RE, Minutello RM, Moussa I, Ho KK, Rogers JH, Shunk KA. Clinical presentation,­management, and outcomes of angiographically documented early, late, and­very late stent thrombosis. JACC Cardiovasc Interv 2012;5(2):131–140

518. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S,­Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G,­Gibson CM, Antman EM. Prasugrel vs. clopidogrel in patients with acute coronary­syndromes. N Engl J Med 2007;357(20):2001–2015

519. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB,­Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S,­Investigators C-O. Dose comparisons of clopidogrel and aspirin in acute coronary­syndromes. N Engl J Med. 2010;363(10):930–942

520. Bonatti JO, Zimrin D, Lehr EJ, Vesely M, Kon ZN, Wehman B, de Biasi AR,­Hofauer B, Weidinger F, Schachner T, Bonaros N, Friedrich G. Hybrid coronary­revascularization using robotic totally endoscopic surgery: perioperative outcomes­and 5-year results. Ann Thorac Surg 2012;94(6):1920–1926; discussion 1926

521. Shen L, HuS,Wang H, Xiong H, Zheng Z, Li L,XuB, Yan H, Gao R. One-stop hybrid­coronary revascularization vs. coronary artery bypass grafting and percutaneous­coronary intervention for the treatment of multivessel coronary artery disease:­3-year follow-up results from a single institution. J Am Coll Cardiol 2013;61(25):­2525–2533

522. Harskamp RE, Bonatti JO, Zhao DX, Puskas JD, de Winter RJ, Alexander JH,­Halkos ME. Standardizing definitions for hybrid coronary revascularization J Thorac Cardiovasc Surg 2014;147(2):556–560

523. Zembala M, Tajstra M, Filipiak K, Knapik P, Hrapkowicz T, Gierlotka M,­Hawranek M, Polonski L, Gasior M. Prospective randomised pilOt study evaLuating­the safety and efficacy of hybrid revascularisation in Multi-vessel coronary artery­DisEaSe (POLMIDES) - study design. Kardiol Pol 2011;69(5):460–466

524. Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia Del Blanco B, Seidelberger B,­Iniguez A, Gomez-Recio M, Masotti M, Velazquez MT, Sanchis J,­Garcia-Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A,­Dominguez A, Mainar V, Lopez-Minguez JR, Moreu J, Marti V, Moreno R,­Jimenez-Quevedo P, Gonzalo N, Fernandez C, Macaya C.ARandomized Comparison­of Drug-Eluting Balloon Vs. Everolimus-Eluting Stent in Patients With Bare-­Metal Stent In-Stent Restenosis: The RIBS V Clinical Trial. J Am Coll Cardiol 2014;­63(14):1378–1386

525. Holmes DR Jr., Davis KB, Mock MB, Fisher LD, Gersh BJ, Killip T 3rd, Pettinger M The effect of medical and surgical treatment on subsequent sudden cardiac death in­patients with coronary artery disease: a report from the Coronary Artery Surgery­Study. Circulation 1986;73(6):1254–1263

526. Veenhuyzen GD, Singh SN, McAreavey D, Shelton BJ, Exner DV. Prior coronary­artery bypass surgery and risk of death among patients with ischemic left ventricular­dysfunction. Circulation 2001;104(13):1489–1493

527. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high­risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary­Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997;­337(22):1569–1575

528. Barsheshet A, Goldenberg I, Moss AJ, Huang DT, ZarebaW, McNitt S, Klein HU,­Guetta V. Effect of elapsed time from coronary revascularization to implantation­of a cardioverter defibrillator on long-term survival in the MADIT-II trial J Cardiovasc Electrophysiol 2011;22(11):1237–1242

529. Al-Khatib SM, Hellkamp AS, Lee KL, Anderson J, Poole JE, Mark DB, Bardy GH,­scd-heft i. Implantable cardioverter defibrillator therapy in patients with prior coronary­revascularization in the Sudden Cardiac Death in Heart Failure Trial­(SCD-HeFT). J Cardiovasc Electrophysiol 2008;19(10):1059–1065

530. Funaro S, La Torre G, Madonna M, Galiuto L, Scara A, Labbadia A, Canali E,­Mattatelli A, Fedele F, Alessandrini F, Crea F, Agati L, Investigators A. Incidence,­determinants, and prognostic value of reverse left ventricular remodelling after­primary percutaneous coronary intervention: results of the Acute Myocardial Infarction­Contrast Imaging (AMICI) multicenter study. Eur Heart J 2009;30(5):­566–575

531. Antoni ML, Mollema SA, Delgado V, Atary JZ, Borleffs CJ, Boersma E, Holman ER,­van derWall EE, Schalij MJ, Bax JJ. Prognostic importance of strain and strain rate­after acute myocardial infarction. Eur Heart J 2010;31(13):1640–1647

532. SesselbergHW, Moss AJ, McNitt S, ZarebaW, Daubert JP, Andrews ML, Hall WJ,­McClinitic B, Huang DT, Group M-IR. Ventricular arrhythmia storms in postinfarction­patients with implantable defibrillators for primary prevention indications: a­MADIT-II substudy. Heart Rhythm 2007;4(11):1395–1402

533. Spaulding CM, Joly LM, Rosenberg A, Monchi M,Weber SN, Dhainaut JF, Carli P Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N­Engl J Med 1997;336(23):1629–1633

534. Kern KB. Optimal treatment of patients surviving out-of-hospital cardiac arrest JACC Cardiovasc Interv 2012;5(6):597–605

535. Garot P, Lefevre T, Eltchaninoff H, Morice MC, Tamion F, Abry B, Lesault PF, Le­Tarnec JY, Pouges C, Margenet A, Monchi M, Laurent I, Dumas P, Garot J,­LouvardY. Six-month outcomeof emergency percutaneous coronary intervention­in resuscitated patients after cardiac arrest complicating ST-elevation myocardial­infarction. Circulation 2007;115(11):1354–1362

536. Radsel P, Knafelj R, Kocjancic S, Noc M. Angiographic characteristics of coronary­disease and postresuscitation electrocardiograms in patients with aborted­cardiac arrest outside a hospital. Am J Cardiol 2011;108(5):634–638

537. Anyfantakis ZA, Baron G, Aubry P, Himbert D, Feldman LJ, Juliard JM,­Ricard-Hibon A, Burnod A, Cokkinos DV, Steg PG. Acute coronary angiographic­findings in survivors of out-of-hospital cardiac arrest. Am Heart J 2009;157(2):­312–318

538. Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J,­Empana JP, Carli P, Mira JP, Jouven X, Spaulding C. Immediate percutaneous coronary­intervention is associated with better survival after out-of-hospital cardiac­arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac­ArresT) registry. Circ Cardiovasc Interv 2010;3(3):200–207

539. Cronier P, Vignon P, Bouferrache K, Aegerter P, Charron C, Templier F, Castro S, El­Mahmoud R, Lory C, Pichon N, Dubourg O, Vieillard-Baron A. Impact of routine­percutaneous coronary intervention after out-of-hospital cardiac arrest due to­ventricular fibrillation. Crit Care 2011;15(3):R122

540. Noc M, Fajadet J, Lassen JF, Kala P, MacCarthy P, Olivecrona GK, Windecker S,­Spaulding C. Invasive Coronary Treatment Strategies for Out-Of-Hospital­Cardiac Arrest:AConsensus Statement from the European Association for Percutaneous­Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups. EuroIntervention­2014;10:31–37

541. Mrdovic I, Savic L, Krljanac G, Perunicic J, Asanin M, Lasica R, Antonijevic N,­Kocev N, Marinkovic J, Vasiljevic Z, Ostojic M. Incidence, predictors, and 30-day­outcomes of new-onset atrial fibrillation after primary percutaneous coronary­intervention: insight into the RISK-PCI trial. Coron Artery Dis 2012;23(1):1–8

542. Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D,­NielsenTT,WeaverWD,Widimsky P, ArmstrongPW, Granger CB. Antithrombotic­therapy and outcomes of patients with atrial fibrillation following primary percutaneous­coronary intervention: results from the APEX-AMI trial. Eur Heart J­2009;30(16):2019–2028

543. Chan W, Ajani AE, Clark DJ, Stub D, Andrianopoulos N, Brennan AL, New G,­Sebastian M, Johnston R,Walton A, Reid CM, Dart AM, Duffy SJ, Melbourne Interventional­Group I. Impact of periprocedural atrial fibrillation on short-termclinical­outcomes following percutaneous coronary intervention. Am J Cardiol 2012;­109(4):471–477

544. Pilgrim T, Kalesan B, Zanchin T, Pulver C, Jung S, Mattle H, Carrel T, Moschovitis A,­Stortecky S, Wenaweser P, Stefanini GG, Raber L, Meier B, Juni P, Windecker S Impact of atrial fibrillation on clinical outcomes among patients with coronary­artery disease undergoing revascularisation with drug-eluting stents. EuroIntervention­2013;8(9):1061–1071

545. Bernard A, Fauchier L, Pellegrin C, Clementy N, Saint Etienne C, Banerjee A,­Naudin D, Angoulvant D. Anticoagulation in patients with atrial fibrillation undergoing­coronary stent implantation. Thromb Haemost 2013;110(3):560–568

546. Ruiz-Nodar JM, Marin F, Roldan V, Valencia J, Manzano-Fernandez S, Caballero L,­Hurtado JA, Sogorb F, Valdes M, Lip GY. Should we recommend oral anticoagulation­therapy in patients with atrial fibrillation undergoing coronary artery stenting­with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv 2012;5(4):­459–466

547. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G,­Kirchhof P, Guidelines ESCCfP. 2012 focused update of the ESC Guidelines for the­management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management­of atrial fibrillation. Developed with the special contribution of the European­Heart Rhythm Association. Eur Heart J 2012;33(21):2719–2747

548. Shen J, Lall S, Zheng V, Buckley P, Damiano RJ Jr., Schuessler RB. The persistent­problem of new-onset postoperative atrial fibrillation: a single-institution experience­over two decades. J Thorac Cardiovasc Surg 2011;141(2):559–570

549. Maesen B, Nijs J, Maessen J, Allessie M, Schotten U. Postoperative atrial fibrillation: a­maze of mechanisms. Europace 2012;14(2):159–174

550. Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P, Cantore C,­Biglioli P, Sala A. Atrial fibrillation after isolated coronary surgery affects late survival Circulation 2008;118(16):1612–1618

551. Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of postoperative­atrial fibrillation and its complications after cardiac surgery: a meta-analysis. Eur­Heart J 2006;27(23):2846–2857

552. Crystal E, Connolly SJ, Sleik K, Ginger TJ, Yusuf S. Interventions on prevention of­postoperative atrial fibrillation in patients undergoing heart surgery: a­meta-analysis. Circulation 2002;106(1):75–80

553. Connolly SJ, Cybulsky I, Lamy A, Roberts RS, O’Brien B, Carroll S, Crystal E,­Thorpe KE, Gent M. Double-blind, placebo-controlled, randomized trial of­prophylactic metoprolol for reduction of hospital length of stay after heart­surgery: the beta-Blocker Length Of Stay (BLOS) study. Am Heart J 2003;145(2):­226–232

554. Lucio EA, Flores A, Blacher C, Leyes PE, Lucchese FA, Ribeiro JP. Effectiveness of­metoprolol in preventing atrial fibrillation and flutter in the postoperative period­of coronary artery bypass graft surgery. Arq Bras Cardiol 2003;82:42–46

555. Tsuboi J, Kawazoe K, Izumoto H, Okabayashi H. Postoperative treatment with carvedilol,­a-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary­artery bypass grafting. Circ J 2008;72:588–591

556. Koniari I, Apostolakis E, Rogkakou C, Baikoussis NG, Dougenis DE. Pharmacologic­prophylaxis for atrial fibrillation following cardiac surgery: a systematic review J Cardiothorac Surg 2010;5:121

557. Dunning J, Treasure T, Versteegh M, Nashef SA. Guidelines on the prevention and­management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J­Cardiothorac Surg 2006;30:852–872

558. Wurdeman RL, Mooss AN, Mohiuddin SM, Lenz TL. Amiodarone vs. sotalol as­prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis Chest 2002;121(4):1203–1210

559. ZhuJ,Wang C,Gao D, Zhang C, ZhangY, LuY,GaoY. Meta-analysis ofamiodarone­vs. beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac­surgery. Intern Med J 2012;42(10):1078–1087

560. El-Chami MF, Kilgo P, Thourani V, Lattouf OM, Delurgio DB, Guyton RA, Leon AR,­Puskas JD. New-onset atrial fibrillation predicts long-termmortality after coronary­artery bypass graft. J Am Coll Cardiol 2010;55(13):1370–1376

561. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R,­Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S,­Page RL, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A,­Wegscheider K, Willems S, Breithardt G. Early and comprehensive management­of atrial fibrillation: executive summary of the proceedings from the 2nd­AFNET-EHRA consensus conference ’research perspectives in AF’. Eur Heart J­2009;30(24):2969–2977c

562. CoxJL,AdN, PalazzoT. Impact of the maze procedureon the strokerate in patients­with atrial fibrillation. J Thorac Cardiovasc Surg 1999;118(5):833–840

563. Garcia-Fernandez MA, Perez-David E, Quiles J, Peralta J, Garcia-Rojas I, Bermejo J,­Moreno M, Silva J. Role of left atrial appendage obliteration in stroke reduction in­patients with mitral valve prosthesis: a transesophageal echocardiographic study J Am Coll Cardiol 2003;42(7):1253–1258

564. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM,­Sick P, Investigators PA. Percutaneous closure of the left atrial appendage vs. warfarin­therapy for prevention of stroke in patients with atrial fibrillation: a randomised­non-inferiority trial. Lancet 2009;374(9689):534–542

565. Bagshaw SM, Galbraith PD, Mitchell LB, Sauve R, ExnerDV, GhaliWA. Prophylactic­amiodarone for prevention of atrial fibrillation after cardiac surgery: a­meta-analysis. Ann Thorac Surg 2006;82:1927–1937

566. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial­appendage closure: results from the Watchman Left Atrial Appendage System­for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the­Continued Access Registry. Circulation 2011;123:417–424

567. Otterstad JE, Kirwan BA, Lubsen J, De Brouwer S, Fox KA, Corell P,­Poole-Wilson PA, Action I. Incidence and outcome of atrial fibrillation in stable­symptomatic coronary disease. Scand Cardiovasc J 2006;40(3):152–159

568. Goldenberg I, Moss AJ, McNitt S, Zareba W, Hall WJ, Andrews ML, Wilber DJ,­Klein HU, Investigators M-I. Time dependence of defibrillator benefit after coronary­revascularization in the Multicenter Automatic Defibrillator Implantation Trial­(MADIT)-II. J Am Coll Cardiol 2006;47(9):1811–1817

569. Wang G, Bainbridge D, Martin J, Cheng D. The efficacy of an intraoperative cell­saver during cardiac surgery: a meta-analysis of randomized trials. Anesth Analg­2009;109(2):320–30

570. McIlroy DR, Myles PS, Phillips LE, Smith JA. Antifibrinolytics in cardiac surgical­patients receiving aspirin: a systematic review and meta-analysis. Br J Anaesth­2009;102(2):168–178

571. Bhaskar B, Dulhunty J, Mullany DV, Fraser JF. Impact of blood product transfusion­on short and long-term survival after cardiac surgery: more evidence. Ann Thorac­Surg 2012;94(2):460–467

572. Jakobsen CJ, Ryhammer PK, Tang M, Andreasen JJ, Mortensen PE. Transfusion of­blood during cardiac surgery is associated with higher long-term mortality in­low-risk patients. Eur J Cardiothorac Surg 2012;42(1):114–120 573. Hajjar LA, Vincent JL, Galas FR, Nakamura RE, Silva CM, Santos MH, Fukushima J,­Kalil Filho R, Sierra DB, Lopes NH, Mauad T, Roquim AC, Sundin MR, Leao WC,­Almeida JP, Pomerantzeff PM, Dallan LO, Jatene FB, Stolf NA, Auler JO Jr. Transfusion­requirements after cardiac surgery: the TRACS randomized controlled trial JAMA 2010;304(14):1559–1567

574. Zenati MA, Shroyer AL, Collins JF, Hattler B, Ota T, Almassi GH, Amidi M,­Novitzky D, Grover FL, Sonel AF. Impact of endoscopic vs. open saphenous vein­harvest technique on late coronary artery bypass grafting patient outcomes in­the ROOBY (Randomized On/Off Bypass) Trial. J Thorac Cardiovasc Surg 2011;­141(2):338–344

575. Lopes RD, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA,­Mehta RH, Gibson CM, Mack MJ, Kouchoukos NT, Califf RM, Alexander JH. Endoscopic­vs. Open Vein-Graft Harvesting in Coronary-Artery Bypass Surgery.NEng J­Med 2009;361(3):235–244

576. Deppe AC, Liakopoulos OJ, Choi YH, Slottosch I, KuhnEW, Scherner M, Stange S,­Wahlers T. Endoscopic vein harvesting for coronary artery bypass grafting: a systematic­review with meta-analysis of 27,789 patients. J Surg Res 2012;180(1):­114–124

577. Yun KL, Wu Y, Aharonian V, Mansukhani P, Pfeffer TA, Sintek CF, Kochamba GS,­Grunkemeier G, Khonsari S. Randomized trial of endoscopic vs. open vein­harvest for coronary artery bypass grafting: six-month patency rates. J Thorac Cardiovasc­Surg 2005;129(3):496–503

578. Ouzounian M, Hassan A, Buth KJ, MacPherson C, Ali IM, Hirsch GM, Ali IS. Impact of­endoscopic vs. open saphenous vein harvest techniques on outcomes after coronary­artery bypass grafting. Ann Thorac Surg 2010;89(2):403–408

579. Williams JB, Peterson ED, Brennan JM, Sedrakyan A, Tavris D, Alexander JH,­Lopes RD, Dokholyan RS, Zhao Y, O’Brien SM, Michler RE, Thourani VH,­Edwards FH, Duggirala H, Gross T, Marinac-Dabic D, Smith PK. Association­between endoscopic vs. open vein-graft harvesting and mortality, wound complications­and cardiovascular events in patients undergoing CABG surgery. JAMA 2012;­308(5):475–484

580. Brown EN,Kon ZN,Tran R, Burris NS,GuJ, Laird P, Brazio PS, Kallam S, Schwartz K,­Bechtel L, Joshi A, Zhang S, Poston RS. Strategies to reduce intraluminal clot formation­in endoscopically harvested saphenous veins. J Thorac Cardiovasc Surg 2007;­134(5):1259–1265

581. Khaleel MS, Dorheim TA, Duryee MJ, Durbin HE Jr., Bussey WD, Garvin RP,­Klassen LW, Thiele GM, Anderson DR. High-pressure distention of the saphenous­vein during preparation results in increased markers of inflammation: a potential­mechanism for graft failure. Ann Thorac Surg 2012;93(2):552–558

582. Rousou LJ, Taylor KB, Lu XG, Healey N, Crittenden MD, Khuri SF, Thatte HS. Saphenous­vein conduits harvested by endoscopic technique exhibit structural and­functional damage. Ann Thorac Surg 2009;87(1):62–70

583. Navia JL, Olivares G, Ehasz P, Gillinov AM, Svensson LG, Brozzi N, Lytle B. Endoscopic­radial artery harvesting procedure for coronary artery bypass grafting Ann Cardiothorac Surg 2013;2(4):557–564

584. Souza DS, Dashwood MR, Tsui JC, Filbey D, Bodin L, Johansson B, Borowiec J Improved patency in vein grafts harvested with surrounding tissue: results of a randomized­study using three harvesting techniques. Ann Thorac Surg 2002;73(4):­1189–1195

Не нашли, что искали? Воспользуйтесь поиском: